# OptimizeRx Corp: Form 8-K, filed Oct 16, 2023

- Company: [OptimizeRx Corp](/companies/oprx.md) (CIK 1448431)
- Form: 8-K
- Filed: 2023-10-16
- Accepted by EDGAR: Oct 16, 2023, 20:31 ET
- Period: 2023-10-11
- Accession: 0001013762-23-004127
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1448431/000101376223004127/ea186749-8k_optimizerx.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1448431/000101376223004127/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.02: Results of operations
- Item 2.03: New direct financial obligation
- Item 3.02: Unregistered sale of equity
- Item 5.02: Departure or appointment of officers or directors
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1448431/000101376223004127/ea186749-8k_optimizerx.htm

Filed Oct 16, 2023.
Source: SEC EDGAR, the filing index for accession 0001013762-23-004127. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.